Ph.D., Founder and CTO, ISK
Yoram is one of founders of ISK Ltd. Based on Novel computational methods Yoram has discovered Nerofe. Nerofe is a novel human peptide hormone that induces death in human cancer cells but not in normal healthy cells. Yoram is responsible for the Nerofe’ technology and Research & Development activities at ISK Ltd. Yoram is also responsible for BD activities at ISK Ltd. Yoram is an expert in deciphering MOA of drugs mainly is area of cancer and diabetes. He serves as a director at Two To Biotech Ltd, an early-stage biotechnology company developing anticancer and diabetes drugs. Dr. Devary holds a Ph.D. degree in Biotechnology from the University of California, San Diego (UCSD). Dr Devary published several papers in distinguished journal such as Cell and Science.
Presentation Title and Company Description
Immunotherapy Showcase: Personalized Immunotherapy: Nerofe and ChemX Combination is a Deadly Anticancer Immunotherapy
ISK Ltd is engaged with developing personalized immunotherapy. ISK’s lead compound Nerofe is a strong activator of both human and mice innate immune response. In vivo experiments have shown that tumors positive for Nerofe’s receptor are very sensitive to NK cells and DC cells following treatment with Nerofe and Chem X. The MOA is unique: Applying Nerofe to mice bearing human tumor positive to Nerofe’s receptor makes the tumor susceptible to death by ChemX and activate mouse innate immune response. Applying low doses of ChemX to these mice make the tumor sensitive to innate immune response. ISK successfully finished phase 1 oncology trial with Nerofe only and is aiming phase 2 using Nerofe and ChemX deadly immunetherapy combination.
ISK Ltd has completed successfully phase 1 oncology trial with its lead compound Nerofe. Patients whose tumors were positive to Nerofe’s receptor had longer PFS periods then patients whose tumors were negative to the receptor. Applying Nerofe to mice bearing human tumor makes the tumor susceptible to death by ChemX and activate mouse innate immune response. Applying low doses of ChemX to these mice make the tumor sensitive to innate immune response. ISK is aiming phase 2 using Nerofe and ChemX combination.